Flamel Technologies to Present at UBS Global Life Sciences Conference


LYON, France—September 18, 2009 - Flamel Technologies (Nasdaq:FLML) today announced that Stephen Willard, Flamel’s chief executive officer, will be presenting at the UBS Global Life Sciences Conference in New York. The presentation will take place at 10:00 AM on September 22nd. A live webcast will be available on Flamel’s website: www.flamel.com.

Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Micropump® is a controlled release and taste-masking technology for the oral administration of small molecule drugs. Flamel's Medusa® technology is designed to deliver controlled-release formulations of proteins, peptides, as well as other large and small molecules..

Contact:

Charles Marlio, Director of Strategic Planning and Investor Relations
Tel:    (011) (33) 4-7278-3434
Fax:   (011) (33) 4-7278-3435
E-mail: marlio@flamel.com

This document contains a number of matters, particularly as related to financial projections and the status of various research projects and technology platforms, that constitute forwardlooking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The presentation reflects the current view of management with respect to future events and is subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks include risks that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements, uncertainties regarding market acceptance of products in development, the impact of competitive products and pricing, and the risks associated with Flamel's reliance on outside parties and key strategic alliances. These and other risks are described more fully in Flamel's Annual Report on the Securities and Exchange Commission Form 20-F for the year ended December 31, 2008.